

# Erick Deconinck

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5270625/erick-deconinck-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

263  
papers

8,648  
citations

52  
h-index

86  
g-index

283  
ext. papers

9,847  
ext. citations

4.5  
avg, IF

4.94  
L-index

#	Paper	IF	Citations
263	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , <b>1999</b> , 94, 1192-1200	2.2	606
262	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , <b>2001</b> , 97, 101-6	2.2	457
261	Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. <i>Blood</i> , <b>2003</b> , 102, 4261-9	2.2	377
260	Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1287-95	59.2	287
259	Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. <i>Blood</i> , <b>2001</b> , 97, 63-72	2.2	245
258	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. <i>Leukemia</i> , <b>2014</b> , 28, 2367-75	10.7	239
257	Elderly patients with aggressive non-Hodgkin lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 2945-53	2.2	181
256	Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1088-97	5.5	181
255	Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 963-71	2.2	180
254	Toxoplasmosis after hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 31, 1188-95	4.6	171
253	Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci� Fran�aise de Greffe de Moelle et de Th�rapie-Cellulaire and the Groupe-Francophone des My�lodysplasies. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4533-40	2.2	160
252	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , <b>2005</b> , 105, 3817-23	2.2	156
251	Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5703-10	2.2	142
250	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 624-36	4.5	128
249	A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. <i>Blood</i> , <b>1996</b> , 88, 2480-2487	2.2	123
248	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , <b>2009</b> , 113, 995-1001	2.2	116
247	Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 159-66	4.5	110

246	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 801-6	4.5	104
245	Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>2003</b> , 14, 277-81	10.3	100
244	Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3848-53	2.2	92
243	Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. <i>Blood</i> , <b>2001</b> , 98, 2640-4	2.2	92
242	Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1238-43	4.7	86
241	Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'étude des Lymphomes de l'Adulte. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 222-229	1.9	86
240	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , <b>2011</b> , 96, 1128-35	6.6	84
239	Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. <i>Haematologica</i> , <b>2009</b> , 94, 542-9	6.6	83
238	Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 2060-4	2.2	82
237	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , <b>2018</b> , 131, 174-181	2.2	78
236	Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2668-76	2.2	78
235	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , <b>2007</b> , 92, 627-34	6.6	78
234	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 788-93	4.7	77
233	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 2099-2110	27.4	75
232	Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1095-104	11.6	74
231	Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. <i>Human Gene Therapy</i> , <b>1997</b> , 8, 615-24	4.8	74
230	Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4940-3	2.2	74
229	Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 780-7	2.2	69

228	The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. <i>Blood</i> , <b>2005</b> , 105, 862-4	2.2	67
227	c-Flip protein expression in Burkitt lymphomas is associated with a poor clinical outcome. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 767-73	4.5	66
226	Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. <i>Blood</i> , <b>2005</b> , 105, 1256-64	2.2	65
225	Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4926-34	2.2	64
224	Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , <b>2005</b> , 43, 5097-101	9.7	64
223	Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. <i>Leukemia</i> , <b>2003</b> , 17, 339-42	10.7	60
222	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , <b>2017</b> , 1, 477-485	7.8	57
221	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2015</b> , 121, 1048-55	6.4	56
220	Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. <i>Transfusion</i> , <b>2007</b> , 47, 1268-75	2.9	55
219	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>Transfusion</i> , <b>2012</b> , 52, 1143-1152	7.1	54
218	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 1317-1328	6.6	54
217	Chromatography in the detection and characterization of illegal pharmaceutical preparations. <i>Journal of Chromatographic Science</i> , <b>2013</b> , 51, 791-806	1.4	54
216	Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. <i>Environment International</i> , <b>2011</b> , 37, 449-53	12.9	54
215	Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 468-475	13.4	53
214	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>European Journal of Haematology</i> , <b>2013</b> , 90, 355-64	3.8	52
213	Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. <i>Transplantation</i> , <b>2013</b> , 95, 1284-91	1.8	52
212	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , <b>2010</b> , 115, 2420-9	2.2	52
211	A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 31, 909-18	4.4	52

210	Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 1111-4	4.4	52
209	A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 811-8	7.1	51
208	In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. <i>Haematologica</i> , <b>2015</b> , 100, 223-30	6.6	49
207	Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. <i>British Journal of Haematology</i> , <b>2000</b> , 109, 736-42	4.5	48
206	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Experimental Hematology</i> , <b>2008</b> , 36, 535-44	3.1	47
205	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 33, 531-4	4.4	45
204	Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. <i>International Journal of Medical Informatics</i> , <b>2010</b> , 79, 699-706	5.3	43
203	Clinical and biological features in -hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients. <i>Haematologica</i> , <b>2019</b> , 104, 1554-1564	6.6	42
202	Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1841-6	4.7	40
201	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2380-2385	10.3	40
200	CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. <i>Cancer Research</i> , <b>2019</b> , 79, 663-675	10.1	38
199	Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. <i>Leukemia</i> , <b>2014</b> , 28, 2422-4	10.7	37
198	Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. <i>Transplantation</i> , <b>1995</b> , 59, 151-5	1.8	36
197	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 372-380	4.4	35
196	Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. <i>Pharmacoeconomics</i> , <b>2010</b> , 28, 35-46	4.4	35
195	Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1260-7	2.2	35
194	Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. <i>Leukemia</i> , <b>2002</b> , 16, 726-35	10.7	35
193	Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. <i>Haematologica</i> , <b>2014</b> , 99, 535-40	6.6	34

192	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , <b>2010</b> , 95, 1350-7	6.6	34
191	Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2014</b> , 39, 168-74	2.2	32
190	Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , <b>2017</b> , 102, 1861-1868	6.6	30
189	Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2012</b> , 5, 27	22.4	29
188	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 751-757	4.7	28
187	Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). <i>European Journal of Haematology</i> , <b>2015</b> , 94, 265-9	3.8	28
186	Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 858-62	4.4	28
185	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , <b>2018</b> , 9, 3379-3393	3.3	28
184	Azole-resistant <i>Aspergillus fumigatus</i> isolate with the TR34/L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 1724-6	9.7	27
183	Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. <i>Leukemia</i> , <b>1998</b> , 12, 213-9	10.7	27
182	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , <b>2019</b> , 3, 4238-4251	7.8	27
181	Ribosomal and mitochondrial DNA target for real-time PCR diagnosis of invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , <b>2011</b> , 49, 1058-63	9.7	26
180	Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 667-75	6.2	26
179	Clinical Profile of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , <b>2019</b> , 134, 734-734	2.2	26
178	CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2012</b> , 81, 17-24	4.6	25
177	Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 556-9	7.1	25
176	Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. <i>Experimental Hematology</i> , <b>2013</b> , 41, 924-33	3.1	24
175	Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 35, 859-68	4.4	24

174	Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 514-520	11.6	23
173	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 207-217	10.3	23
172	Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?. <i>Human Gene Therapy</i> , <b>2008</b> , 19, 937-50	4.8	23
171	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , <b>2020</b> , 7, e50-e60	14.6	23
170	Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , <b>1997</b> , 20, 975-82	4.4	22
169	Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. <i>Transplantation</i> , <b>2002</b> , 74, 1190-2	1.8	22
168	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , <b>2017</b> , 178, 521-533	4.5	21
167	Evaluation of invasive aspergillosis risk of immunocompromised patients alternatively hospitalized in hematology intensive care unit and at home. <i>Indoor Air</i> , <b>2014</b> , 24, 652-61	5.4	21
166	False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease. <i>Medical Mycology</i> , <b>2010</b> , 48, 661-4	3.9	21
165	Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). <i>Bone Marrow Transplantation</i> , <b>1997</b> , 20, 731-5	4.4	21
164	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. <i>Haematologica</i> , <b>2018</b> , 103, 2033-2039	6.6	19
163	Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report. <i>Liver Transplantation</i> , <b>2009</b> , 15, 682-5	4.5	19
162	Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. <i>Blood</i> , <b>2007</b> , 110, 3842-52	2.2	19
161	A 10-year survey of fungal aerocontamination in hospital corridors: a reliable sentinel to predict fungal exposure risk?. <i>Journal of Hospital Infection</i> , <b>2014</b> , 87, 34-40	6.9	18
160	Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage I-II patients. <i>Annals of Oncology</i> , <b>1997</b> , 8, S49-S52	10.3	18
159	Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11, 359-68	1.9	18
158	EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1391-1398	4.4	17
157	Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. <i>Annals of Oncology</i> , <b>2005</b> , 16, 166-72	10.3	17

156	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocéf-Goelams Randomized Phase II Trial (PRECIS). <i>Blood</i> , <b>2016</b> , 128, 782-782	2.2	17
155	Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 635-642	7.1	16
154	Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: lack of lymphocyte recovery as a major contributing factor. <i>Pathologie Et Biologie</i> , <b>2014</b> , 62, 156-61		16
153	Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2012</b> , 81, 718-24	4.6	16
152	Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? [letter; comment]. <i>Blood</i> , <b>1992</b> , 80, 2149-2150	2.2	16
151	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1987-1994	4.4	15
150	Retrospective assessment of ED-(1,3)-glucan for presumptive diagnosis of fungal infections. <i>Apmis</i> , <b>2011</b> , 119, 280-6	3.4	15
149	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , <b>2018</b> , 283, 371-379	10.8	15
148	Development of a quantitative PCR detecting <i>Cunninghamella bertholletiae</i> to help in diagnosing this rare and aggressive mucormycosis. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1180-1183	4.4	14
147	Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2016</b> , 101, 1120-7	6.6	14
146	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , <b>2020</b> , 34, 3228-3241	10.7	13
145	A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. <i>Leukemia Research Reports</i> , <b>2013</b> , 2, 29-31	0.6	13
144	Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1134-9	4.7	13
143	G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. <i>Blood</i> , <b>2010</b> , 115, 910-1	2.2	13
142	Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , <b>1998</b> , 21, 943-6	4.4	13
141	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 88	7	13
140	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 416-423	7.1	12
139	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2647-2657	2.2	11



138	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 87	22.4	11
137	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2102	59.2	11
136	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 653-659	7.1	10
135	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. <i>Blood Advances</i> , <b>2021</b> , 5, 1540-1551	7.8	10
134	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 344-350	7.1	9
133	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. <i>Experimental Hematology and Oncology</i> , <b>2015</b> , 5, 7	7.8	9
132	Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytopheresis in normal peripheral blood stem cell donors. <i>Transfusion</i> , <b>2010</b> , 50, 2676-85 <sup>9</sup>		9
131	Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Soci�t� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1452-9	4.7	8
130	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Soci�t� Fran�aise de Greffe de Moelle et	4.7	8
129	Combining Aspergillus mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients. <i>Medical Mycology</i> , <b>2015</b> , 53, 760-4	3.9	8
128	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and	4.7	8
127	Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. <i>Pharmacoeconomics</i> , <b>2009</b> , 27, 55-68	4.4	8
126	The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.. <i>Blood</i> , <b>2019</b> , 134, 494-494	2.2	8
125	Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. <i>Haematologica</i> , <b>2021</b> , 106, 3056-3066	6.6	8
124	Identification of (antioxidative) plants in herbal pharmaceutical preparations and dietary supplements. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1208, 181-99	1.4	8
123	Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation. <i>Platelets</i> , <b>2020</b> , 31, 536-540	3.6	8
122	Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1586-84	4.4	7
121	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 449-55	3.8	7

120	Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant. <i>Mycopathologia</i> , <b>2017</b> , 182, 761-765	2.9	7
119	Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients involvement in specific therapies decision-making. <i>BMC Palliative Care</i> , <b>2015</b> , 14, 61	3	7
118	A single intravenous infusion of apoptotic cells, an alternative cell-based therapy approach facilitating hematopoietic cell engraftment, did not induce autoimmunity. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2003</b> , 12, 451-9		7
117	No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial. <i>Blood</i> , <b>2010</b> , 116, 685-685	2.2	7
116	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 231-239	7.1	7
115	Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2181-2188	10.3	6
114	Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 491-500	3.1	6
113	Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice. <i>Medical Mycology</i> , <b>2014</b> , 52, 728-35	3.9	6
112	Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 269-72	3.8	6
111	Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 935-40	4.7	6
110	Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 622-4	4.4	6
109	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , <b>2010</b> , 116, 910-910	2.2	6
108	Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts. <i>Gene Therapy</i> , <b>2016</b> , 23, 664-72	4	6
107	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN analyzers in routine laboratory practice. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2018</b> , 78, 159-164	2	5
106	Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 177-80	4.4	5
105	Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin Lymphoma. <i>Clinical Drug Investigation</i> , <b>2005</b> , 25, 719-29	3.2	5
104	High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura. <i>American Journal of Hematology</i> , <b>1996</b> , 51, 334	7.1	5
103	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5

102	Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate. <i>Acta Dermato-Venereologica</i> , <b>2015</b> , 95, 495-6	2.2	4
101	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 599933	5.3	4
100	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1057-1065	7.1	4
99	CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , <b>2020</b> , 95, 892-899	7.1	4
98	Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study. <i>Transfusion</i> , <b>2018</b> , 58, 1377-1387	2.9	4
97	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 2060-2071	4.4	4
96	Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 250-6	4.7	4
95	Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells. <i>Molecular Immunology</i> , <b>2013</b> , 56, 123-8	4.3	4
94	Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation. <i>Blood</i> , <b>2011</b> , 118, 476-8	2.2	4
93	Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 448-54	4.7	4
92	Quantification de <i>Stachybotrys chartarum</i> par PCR en temps réel dans l'environnement domestique, hospitalier, et agricole. <i>Journal De Mycologie Medicale</i> , <b>2006</b> , 16, 183-188	3	4
91	High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>1998</b> , 9 Suppl 1, S5-8	10.3	4
90	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2254-2260	4.4	4
89	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , <b>2020</b> , 34, 1144-1153	10.7	4
88	DNA damage response defect in Williams-Beuren syndrome. <i>International Journal of Molecular Medicine</i> , <b>2017</b> , 39, 622-628	4.4	3
87	Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation. <i>Hematology and Cell Therapy</i> , <b>1999</b> , 41, 31-7		3
86	Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group. <i>Blood</i> , <b>2010</b> , 116, 13-13	2.2	3
85	Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant Disorders. A Eurocord-EBMT Analysis. <i>Blood</i> , <b>2010</b> , 116, 223-223	2.2	3

84	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , <b>2012</b> , 120, 906-906 <sup>2.2</sup>	3
83	Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT. <i>Blood</i> , <b>2013</b> , 122, 2156-2156	2.2 3
82	How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network. <i>Blood</i> , <b>2015</b> , 126, 456-456	2.2 3
81	A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. <i>The Hematology Journal</i> , <b>2004</b> , 5, 209-15	3
80	Structural study of L-ascorbic acid 2-phosphate magnesium, a raw material in cell and tissue therapy. <i>Journal of Biological Inorganic Chemistry</i> , <b>2020</b> , 25, 875-885	3.7 3
79	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 592-601	4.5 3
78	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1305-1315	4.4 3
77	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 1597-1609	10.7 3
76	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , <b>2017</b> , 54, 12-16	2.7 2
75	Altered thymic CD4 T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis. <i>Current Research in Translational Medicine</i> , <b>2019</b> , 67, 135-143	3.7 2
74	Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Bone Marrow Transplantation</i> , <b>2013</b> , 48, 684-90	4.4 2
73	Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1697-702	4.3 2
72	Renal toxicity after bone marrow transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 58, 661-2	4 2
71	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. <i>Blood</i> , <b>2008</b> , 112, 139-139	2.2 2
70	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial. <i>Blood</i> , <b>2010</b> , 116, 1344-1344	2.2 2
69	Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial. <i>Blood</i> , <b>2013</b> , 122, 2691-2691	2.2 2
68	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. <i>Blood</i> , <b>2014</b> , 124, 187-187	2.2 2
67	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 605-613	4.4 2

66	Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 834-836	3.6	1
65	Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 613-620	3.1	1
64	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1135	7.1	1
63	E-santé et organisation des soins : structuration de la thérapeutique anti-cancéreuse en Franche-Comté <i>European Research in Telemedicine</i> , <b>2013</b> , 2, 101-107		1
62	Polyvisceral arteritis in chronic graft-versus-host disease: antiphospholipid-negative thrombotic syndrome mimicking polyarteritis nodosa. <i>Bone Marrow Transplantation</i> , <b>2002</b> , 29, 873-4	4.4	1
61	Transgene Deletions in Long-Term Circulating Donor Gene-Modified T Lymphocytes Infused at Time of Hematopoietic Transplantation.. <i>Blood</i> , <b>2005</b> , 106, 461-461	2.2	1
60	Complete Remission After First-Line Radio Plus Chemotherapy Is Enough to Improve Survival in Extra Nodal NK/T Cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 2679-2679	2.2	1
59	Two Years Follow-up Results of Graspall/Graall-SA2008 Study: L-Asparaginase-Loaded Red Blood Cell Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). <i>Blood</i> , <b>2012</b> , 120, 1473-1473	2.2	1
58	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , <b>2012</b> , 120, 890-890	2.2	1
57	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. <i>Blood</i> , <b>2014</b> , 124, 545-545	2.2	1
56	Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2015</b> , 126, 3111-3111	2.2	1
55	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. <i>Blood</i> , <b>2015</b> , 126, 3214-3214	2.2	1
54	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , <b>2018</b> , 132, 248-248	2.2	1
53	Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1140-2	4.4	1
52	Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman. <i>Case Reports in Hematology</i> , <b>2020</b> , 2020, 3686584	0.7	1
51	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , <b>2021</b> , 60, 466-474	3.2	1
50	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 655-663	4.4	1
49	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1077-1085	4.4	1

48	Platelet transfusions in haematologic malignancies in the last six months of life. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 425-433	3.1	1
47	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , <b>2021</b> , 35, 1291-1300	10.7	1
46	Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study. <i>Blood</i> , <b>2015</b> , 126, 1922-1922	2.2	0
45	Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?. <i>Vaccine</i> , <b>2021</b> , 39, 7036-7043	4.1	0
44	Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. <i>Blood Advances</i> , <b>2020</b> , 4, 6327-6335	7.8	0
43	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , <b>2014</b> , 124, 1230-1230	2.2	0
42	Oral therapy adherence and satisfaction in patients with multiple myeloma. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1803-1813	3	0
41	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Blood Advances</i> , <b>2021</b> , 5, 181-181	4.4	0
40	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , <b>2021</b> , 35, 2332-2345	10.7	0
39	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1563-1572	4.4	0
38	Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) Resolves Gastrointestinal Disorders in a Patient with Severe Idiopathic Aplastic Anaemia. <i>Drugs</i> , <b>2006</b> , 66, 337-335	12.1	
37	Aplasie post-chimiothérapie et autogreffe de moelle osseuse: apport des facteurs de croissance hématopoïétiques. <i>Revue De Medecine Interne</i> , <b>1991</b> , 12, S271-S273	0.1	
36	Cidofovir: A Treatment for BK Virus Cystitis after Allogenic Bone Marrow Transplantation.. <i>Blood</i> , <b>2005</b> , 106, 5354-5354	2.2	
35	Refractory Hemorrhagic Cystitis after Hematopoietic Stem Cell Transplantation: Clinical Benefit of Factor XIII.. <i>Blood</i> , <b>2007</b> , 110, 4935-4935	2.2	
34	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC. <i>Blood</i> , <b>2018</b> , 132, 4663-4663	2.2	
33	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. <i>Blood</i> , <b>2018</b> , 132, 4390-4390	2.2	
32	Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT. <i>Blood</i> , <b>2019</b> , 134, 4548-4548	2.2	
31	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2019</b> , 134, 3338-3338	2.2	

- 30 The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. *Blood*, **2014**, 124, 681-681 2.2
- 29 Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. *Blood*, **2014**, 124, 2581-2581 2.2
- 28 Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. *Blood*, **2014**, 124, 3945-3945 2.2
- 27 Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study. *Blood*, **2015**, 126, 3203-3203 2.2
- 26 Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC. *Blood*, **2015**, 126, 5444-5444 2.2
- 25 Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French 2.2
- 24 Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). *Blood*, **2015**, 126, 4367-4367 2.2
- 23 Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA. *Blood*, **2015**, 126, 1946-1946 2.2
- 22 Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia. *Blood*, **2015**, 128, 5069-5069 2.2
- 21 Autologous Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). *Blood*, **2015**, 128, 3370-3370 2.2
- 20 Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. *Blood*, **2015**, 128, 3467-3467 2.2
- 19 Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. *Blood*, **2016**, 128, 2899-2899 2.2
- 18 Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM. *Blood*, **2016**, 128, 3569-3569 2.2
- 17 Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. *Blood*, **2016**, 128, 3476-3476 2.2
- 16 Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. *Blood*, **2016**, 128, 895-895 2.2
- 15 Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT. *Blood*, **2016**, 128, 2280-2280 2.2
- 14 Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. *Blood*, **2010**, 116, 2171-2171 2.2
- 13 Disease Status Is the Major Prognosis Factor for Allogeneic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). *Blood*, **2010**, 116, 2359-2359 2.2

12	The IL-3R $\alpha$ -Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. <i>Blood</i> , <b>2011</b> , 118, 2588-2588	2.2
11	L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph- ALL): First Results of the GRASPALL/GRAALL-SA2-2008 Study. <i>Blood</i> , <b>2011</b> , 118, 2579-2579	2.2
10	Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group. <i>Blood</i> , <b>2011</b> , 118, 3035-3035	2.2
9	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , <b>2012</b> , 120, 1875-1875	2.2
8	Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe franc aise De Greffe De Moelle Et De Therapie Cellulaire. <i>Blood</i> , <b>2012</b> , 120, 2008-2008	2.2
7	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL: Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , <b>2013</b> , 122, 495-495	2.2
6	Antithymocyte Globulin and Role Of Stem Cell Source On Outcome In Myeloablative Conditioning Of Allogeneic Hematopoietic Stem Cell Transplantation With Identical Sibling and Matched Unrelated Donors - A Retrospective Study Of French Society Of Bone Marrow Graft Transplantation and Cellular Therapy - <i>Blood</i> , <b>2013</b> , 122, 3382-3382	2.2
5	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients: A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , <b>2013</b> , 122, 921-921	2.2
4	Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, <i>Aspergillus fumigatus</i> qPCR, and <i>Mucorales</i> qPCR. <i>Journal De Mycologie Medicale</i> , <b>2021</b> , 31, 101117	3
3	BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity. <i>EJHaem</i> , <b>2021</b> , 2, 128-133	0.9
2	Lymphoblastic T Cells and Mature NK Cells With the Same TCR $\beta$ Rearrangement: A Common Origin?. <i>HemaSphere</i> , <b>2021</b> , 5, e608	0.3
1	A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child. <i>Leukemia Research Reports</i> , <b>2021</b> , 16, 100262	0.6